Feb 24 (Reuters) – CymaBay Therapeutics Inc stated its experimental lead drug met the primary intention of lowering episodes of gout in a mid-stage find out about.
The corporate mentioned the drug, arhalofenate, used to be proven to be protected and smartly tolerated.
Gout is a situation affecting joints and muscle tissue when the physique acts towards a construct-up of uric acid within the blood. (Reporting via Rosmi Shaji in Bengaluru; Enhancing by means of Saumyadeb Chakrabarty)
<div id="proGrids10066"/>
<div id="crp_related" class="crp_related">Related Posts:
The corporate mentioned the drug, arhalofenate, used to be proven to be protected and smartly tolerated.
Gout is a situation affecting joints and muscle tissue when the physique acts towards a construct-up of uric acid within the blood. (Reporting via Rosmi Shaji in Bengaluru; Enhancing by means of Saumyadeb Chakrabarty)
<div id="proGrids10066"/>
- CymaBay’s gout drug meets major purpose in mid-stage… February 24, 2015 (Reuters) - CymaBay Therapeutics Inc mentioned its experimental lead drug…
- CytRx most cancers drug displays promise in mid-stage learn… January 8, 2015 (Reuters) - CytRx Corp stated its most cancers drug used…
- Alkermes schizophrenia drug meets major intention in… January 7, 2015 Jan 7 (Reuters) - Alkermes %said itsexperimental drug to deal…
- CytRx most cancers drug displays promise in mid-stage learn… January 8, 2015 Jan eight (Reuters) - CytRx Corp mentioned its most cancers…
- Portola’s drug reverses impact of J&J’s… January 9, 2015 Jan 9 (Reuters) - Portola Prescription drugs Inc stated its…
via Smart Health Shop Forum http://ift.tt/1zcA9D7
No comments:
Post a Comment